What is Wedbush's Forecast for Nuvation Bio Q1 Earnings?

Nuvation Bio Inc. (NYSE:NUVB - Free Report) - Equities research analysts at Wedbush issued their Q1 2026 EPS estimates for Nuvation Bio in a research report issued on Thursday, March 6th. Wedbush analyst D. Nierengarten expects that the company will post earnings per share of ($0.23) for the quarter. Wedbush currently has a "Outperform" rating and a $5.00 price target on the stock. The consensus estimate for Nuvation Bio's current full-year earnings is ($0.36) per share. Wedbush also issued estimates for Nuvation Bio's Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.22) EPS and Q4 2026 earnings at ($0.21) EPS.

Several other analysts have also commented on NUVB. Royal Bank of Canada reiterated an "outperform" rating and issued a $10.00 price target (up from $6.00) on shares of Nuvation Bio in a research report on Tuesday, January 7th. Jones Trading began coverage on Nuvation Bio in a report on Wednesday. They set a "buy" rating and a $10.00 target price on the stock. Finally, HC Wainwright cut their price target on Nuvation Bio from $11.00 to $10.00 and set a "buy" rating for the company in a report on Monday. Six analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $8.33.

Nuvation Bio Trading Down 1.1 %

Shares of NUVB stock traded down $0.03 during mid-day trading on Monday, reaching $2.22. The stock had a trading volume of 3,128,941 shares, compared to its average volume of 2,644,780. Nuvation Bio has a 12-month low of $1.67 and a 12-month high of $4.16. The business has a 50-day simple moving average of $2.38 and a 200 day simple moving average of $2.57. The company has a market cap of $745.50 million, a P/E ratio of -1.03 and a beta of 1.47.

Remove Ads

Hedge Funds Weigh In On Nuvation Bio

Large investors have recently added to or reduced their stakes in the business. GSA Capital Partners LLP purchased a new stake in Nuvation Bio in the third quarter valued at approximately $172,000. Connor Clark & Lunn Investment Management Ltd. raised its stake in Nuvation Bio by 9.0% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 396,736 shares of the company's stock worth $909,000 after purchasing an additional 32,811 shares during the period. Intech Investment Management LLC purchased a new stake in shares of Nuvation Bio during the 3rd quarter valued at $132,000. Charles Schwab Investment Management Inc. increased its holdings in shares of Nuvation Bio by 4.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,394,015 shares of the company's stock worth $3,192,000 after buying an additional 60,590 shares during the last quarter. Finally, Meridian Wealth Management LLC raised its position in shares of Nuvation Bio by 47.0% in the 3rd quarter. Meridian Wealth Management LLC now owns 82,840 shares of the company's stock worth $190,000 after buying an additional 26,495 shares during the period. 61.67% of the stock is currently owned by hedge funds and other institutional investors.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.